Breaking News

Curia Enters Agreement with U.S. Govt. to Expand Sterile Fill-Finish Capability

The 65,000-sq.-ft. expansion includes two 430-sq.-ft. lyophilizers, automated visual inspection technology, automated packaging capacity, ultra-cold storage.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Curia, formerly AMRI, a contract research, development and manufacturing organization, entered a cooperative agreement with the Biomedical Advanced Research and Development Authority’s (BARDA) Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, to support the domestic production of injectable medicines. This agreement includes funding to add a new advanced isolated high-speed fill-finish vial line – which includes biosafety level 2 (BS...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters